Datavant, a fledgling spinoff from Roivant Sciences, is trying to break down information silos that often lead to poorly designed clinical trials.

Version 5.0 of the software features tools for normalizing concepts such as gene mutations and additional query features for mining text documents.

The launch follows a beta that kicked off earlier this year to put the software through its paces with data curators and other scientists.

The resource will offer easy access to an inventory of vendors with patient-derived xenograph models as well as associated molecular data for oncology drug discovery projects.

The custom software development company will soon test a tool called 5AM Sunrise for managing and aggregating clinical and molecular data.

The company is working on a bespoke pharmacovigilance product that will leverage its biomedical content, and has added an NGS module to Pathway Studio. 

The company will use some of the funds to set up a new research laboratory within the US to better support collaborations with pharma and biotech.

Lonza now offers kits and services featuring Roche's MycoTool detection kits for final release testing of pharmaceutical products, upon validation. In the meantime, Lonza continues to develop its own pharma QC products, including mycoplasma detection assays, on BD's automated testing platform.

BD Diagnostics and Switzerland's Lonza have inked an agreement to develop and commercialize Lonza's microCompass molecular assays on the BD Max system for pharmaceutical quality-control testing.

HCP and BioMed Realty, two of the nation's largest publicly-traded owners of life sciences space, offered largely upbeat updates on their businesses this week following the release of their quarterly financial results.


Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.